Clinical Study on the EBV CAR-T /TCR-T Cells in the Treatment of Nasopharyngeal Carcinoma

This study was a single-arm, open-label, "3 + 3" dose-escalation Exploratory research. The patients were divided into two groups: EBV TCR-T-cell Group and EBV CAR-T-cell group. The EBV CAR-T-treated group received three progressively increasing dose levels (3.0 × 106 cells/kg, 9.0 × 106 cells/kg, 1.5 × 107 cells/kg) of EBV CAR-T-cell therapy; The EBV TCR-T-cell group received three progressively increasing doses (5.0 × 106 cells/kg, 1.5 × 107 cells/kg, 3.0 × 107 cells/kg) of EBV TCR-T-cell therapy.

Trial Details

NCT ID
NCT05587543
Phase
EARLY_PHASE1
Sponsor
Fudan University
Status
RECRUITING
Cancer Type
Nasopharyngeal Head and Neck Cancer
Interventions
  • PK Blood Collection
  • CAR
  • TCR
Locations (sample)
  • Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

  • Voluntary written informed consent;
  • Age ≥18 years old, ≤75 years old, male and female;
  • Expected survival ≥3 months;
  • The Eastern Cooperative Oncology Group (ECOG) physical fitness score was 0-2;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Nasopharyngeal Head and Neck Cancer Trials on Trialify →